Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content

Devika Ganesamoorthy1,2*, Alan James Robertson1, Wenhan Chen1, Michael B. Hall1, Minh Duc Cao1, Kaltin Ferguson3, Sunil R. Lakhani3,4, Katia Nones5, Peter T. Simpson3 and Lachlan J. M. Coin1,2,6,7*

Abstract

Background: Circulating cell-free DNA (cfDNA) in the plasma of cancer patients contains cell-free tumour DNA (ctDNA) derived from tumour cells and it has been widely recognized as a non-invasive source of tumour DNA for diagnosis and prognosis of cancer. Molecular profiling of ctDNA is often performed using targeted sequencing or low-coverage whole genome sequencing (WGS) to identify tumour specific somatic mutations or somatic copy number aberrations (sCNAs). However, these approaches cannot efficiently detect all tumour-derived genomic changes in ctDNA.

Methods: We performed WGS analysis of cfDNA from 4 breast cancer patients and 2 patients with benign tumours. We sequenced matched germline DNA for all 6 patients and tumour samples from the breast cancer patients. All samples were sequenced on Illumina HiSeqXTen sequencing platform and achieved approximately 30x, 60x and 100x coverage on germline, tumour and plasma DNA samples, respectively.

Results: The mutational burden of the plasma samples (1.44 somatic mutations/Mb of genome) was higher than the matched tumour samples. However, 90% of high confidence somatic cfDNA variants were not detected in matched tumour samples and were found to comprise two background plasma mutational signatures. In contrast, cfDNA from the di-nucleosome fraction (300 bp–350 bp) had much higher proportion (30%) of variants shared with tumour. Despite high coverage sequencing we were unable to detect sCNAs in plasma samples.

Conclusions: Deep sequencing analysis of plasma samples revealed higher fraction of unique somatic mutations in plasma samples, which were not detected in matched tumour samples. Sequencing of di-nucleosome bound cfDNA fragments may increase recovery of tumour mutations from plasma.

Keywords: Cell-free DNA, Cell-free tumour DNA, Somatic mutations, Mutational signatures

Background

Cell-free DNA (cfDNA) is an emerging non-invasive biomarker for diagnosis and prognosis of various acute and chronic disorders. cfDNA has been detected in many body fluids, including plasma, serum, urine and cerebrospinal fluid [1]. cfDNA is predominantly of hematopoietic origin [2], however recent studies have showed release of cfDNA from other organs and tissues into the extracellular compartments [3–5]. The connection of
cfDNA with several tissues and organs in the body makes it an attractive non-invasive biomarker for various diseases including cancer.

Cell-free tumour DNA (ctDNA) derived from cancerous cells can be detected in blood [6] and it has provided new avenues for non-invasive detection and monitoring of cancer [7]. Tumour-specific alterations such as somatic copy number aberrations (sCNAs) and single nucleotide variants (SNVs) have been detected in the plasma of cancer patients [8]. ctDNA has been detected in both early and late stage tumours [9] and the utility of ctDNA as a biomarker has been assessed for various cancer types with promising results [10]. The levels of ctDNA can be used as an early diagnostic marker and to monitor changes during therapy [11–13].

Currently the gold standard approach for tumour diagnosis involves biopsy sampling. However, the invasive nature of the biopsy sampling process restricts its use. It is not feasible for frequent sampling; the size and the location of the tumour also imposes limitations. Moreover, a biopsy only samples part of the tumour, hence, only represents a fraction of the possible heterogeneity observed in many tumours. ctDNA on the other hand can be obtained by a single blood draw allowing for multiple sampling. Also, as ctDNA is derived from various tumour clones and sites, it provides a comprehensive representation of the tumour heterogeneity in the patient [5]. These features make them an ideal biomarker for cancer diagnosis and monitoring.

Levels of ctDNA can vary between different cancer types and often early stage cancers have very low levels of ctDNA in plasma [9], making it difficult to measure. To enable accurate detection of ctDNA, targeted approaches such as quantitative PCR for specific gene mutations or copy number changes associated with cancer are widely used [14–16]. Targeted sequencing approaches using gene panels or exome panels have been utilised to enable testing of more targets in cfDNA [17, 18].

To date, most sequencing approaches on cfDNA for the detection of tumour-derived genomic alterations have been based on either targeted sequencing approaches or low-coverage whole genome sequencing (WGS) approaches. Higher sequencing coverage achievable via targeted approaches have facilitated detection of cancer related mutations even in samples with low ctDNA [19]. However targeted sequencing approaches cannot capture all genomic changes, such as structural rearrangements. Low-coverage WGS approaches are widely utilised to assess CNAs in ctDNA [20–23]. The size of the CNAs and the levels of ctDNA in the sample affects the efficiency of this approach [24]. In contrast to targeted sequencing, single nucleotide mutations cannot be accurately detected using low-coverage WGS approach.

The cost associated with sequencing approaches has mainly hindered the use of high-coverage WGS approaches on cfDNA. However, simultaneous detection of gene mutations and CNAs in cfDNA can be achieved by WGS approaches [8, 25]. In this study, we aim to explore the utility of high-coverage WGS of cfDNA in cancer diagnosis. We performed high-coverage (~100X coverage) WGS analysis of cfDNA from patients with breast tumours and patients with benign tumours. We identified a large fraction of somatic mutations in cfDNA samples not detected in matched tumour samples and identified specific somatic mutational signatures in these samples. We also explored the differences in fragment size distribution in cfDNA samples.

Methods
Sample collection
Four patients with breast cancer (1084, 1249, 1494 and 1524) and 2 patients with benign tumours (065 and 098) were included in this study. Tumour characteristics of these samples are provided in Supplementary Table 1. These patients were recruited by the Brisbane Breast Bank [26], which was approved by the Human Research Ethics Committee at the University of Queensland (Project ID: 2005000785) and the Royal Brisbane and Women’s Hospital (Ref. 2005/022). Tumour tissue samples were collected during surgery and blood samples were collected prior to the surgery from these patients. Tumour samples from benign tumour patients were not sequenced.

EDTA blood tubes were processed on the same day (between 1.5 to 5 h) of collection. Blood samples were centrifuged at 3000 rpm for 10 min to separate blood cells and plasma. The buffy coat was stored at -20°C for germline DNA extraction. Plasma aliquots were re-centrifuged at 13000 rpm for 10 min and the plasma was stored at -80°C for plasma cfDNA extraction. Tissue samples from tumours were snap frozen in liquid nitrogen and stored in − 80 degrees freezer.

DNA extraction
Plasma cfDNA was extracted using Circulating Cell free Nucleic Acid kit (Qiagen) according to manufacturer’s instructions. Germline DNA from Buffy coat was extracted using the QIAamp DNA Blood Mini kit (Qiagen) and tumour DNA from tissue samples were extracted using the AllPrep Universal kit (Qiagen) according to manufacturer’s instructions.

Library preparation
Libraries for sequencing were prepared using the TruSeq Nano HT Kit (Illumina) according to manufacturer’s instructions with minor modifications for plasma cfDNA.
samples. Briefly germline and tumour DNA samples (100 ng input DNA) were fragmented to 350 bp and a size selection step was performed after the end repair process to remove small fragments. However, due to the nature of plasma cfDNA (20 ng input DNA), which consists of short DNA fragments, fragmentation and size selection were omitted during the library preparation. The rest of the process were similar for all DNA samples and prepared according to the manufacturer's instructions.

Libraries were sequenced on Illumina HiSeqXTen and 150 bp paired-end sequencing was performed. Samples were sequenced at varying coverage for each sample type; plasma cfDNA samples were sequenced in 4 lanes of HiSeqXTen per sample, tumour samples were sequenced in 2 lanes per sample and germline DNA samples were sequenced in 1 lane to achieve 120X, 60X and 30X coverage respectively.

**Pre-processing of sequencing reads**

FastQC [27] was used to assess the quality of the FastQ files. Trimmomatic (v0.32) [28] was used to trim Illumina adapter sequences and low quality bases (base quality less than 30) in both ends of the read. Also reads less than 35 bp in length were discarded. Base quality was low towards the end of the read, therefore all reads were trimmed to 145 bp regardless of quality using fastx_trimmer (FASTX-Toolkit [29]).

Sequence reads were aligned to human genome hg19 reference version using BWA MEM [30]. Samtools (v1.3) [31] was used to filter out supplementary alignments. MarkDuplicates option in Picard tools [32] was used to identify duplicated reads. Scripts used for processing of sequencing reads are provided in https://github.com/Devika1/Plasma_HiSeqXTen.

**Somatic variant analysis**

Somatic single nucleotide variant (SNV) detection was performed using VarScan2 (version 2.4.4) [33] for both tumour and plasma samples. Samtools (v1.10) [31] mpileup with default settings (except minimum mapping quality of 2) was used to generate the input for VarScan2 variant calling. Samtools mpileup, by default considers overlapping reads and counts them only once and ignores duplicated reads in the read counts. VarScan2 with somatic option was used with default settings, except 0.01 frequency was used for ‘min-var-freq’ option. The output was then processed with processSomatic option with default settings, except for --min-tumor-freq 0.01 and --max-normal-freq 0.00 to identify high confidence somatic variants. These high confidence variants were further filtered with fpfilter option with default settings except for --min-var-freq 0.01 to remove false positive variants. Bam-readcount (version 0.8.0, https://github.com/genome/bam-readcount) was used to calculate readcounts, mapping quality and base quality at the variant positions and this information was used in the fpfilter to determine false positive variants. Output from fpfilter were filtered further using the following thresholds to identify high confidence somatic variants:

i) At least 10x coverage for germline and tumour sample
ii) At least 5 reads supporting the variant allele in tumour sample
iii) 0 reads in germline for the variant allele

**Variant annotation**

Somatic variants identified from VarScan2 were annotated using Annovar [34] and hg19 human databases were used for annotation. Somatic variants which were shared between tumour and plasma samples were identified using custom awk scripts (provided in https://github.com/Devika1/Plasma_HiSeqXTen).

**Somatic reads enrichment**

Reads supporting somatic variants were used for downstream analysis and these reads were extracted using a java package JAPSA (https://github.com/mdcao/japsa). The somatic reads extraction tool was deployed using script name jsa.h.ts.aareads. Filtered somatic output from VarScan2 (to provide position of somatic variants) and aligned bam file was used as input to extract reads containing the somatic variant (script provided in https://github.com/Devika1/Plasma_HiSeqXTen).

**Mutational signature analysis**

Mutational Patterns [35] was used to identify mutational signatures from the somatic mutation data. Somatic SNVs (specifically single base substitutions) from plasma and tumour samples were used for mutational signature analysis. Mutational Patterns R package was used for analysis (https://github.com/UMCUGenetics/MutationalPatterns). De novo mutational signature extraction was performed using Non-negative Matrix Factorization (NMF). Contributions of known COSMIC mutational signatures (version 2) (https://cancer.sanger.ac.uk/cosmic/signatures_v2) for SNVs were determined from the mutational profiles of each samples and this information was used to determine the mutational process.

**Somatic CNAs analysis**

Somatic copy number aberration (CNA) analysis was performed using IchorCNA [18]. Readcounts for IchorCNA analysis were generated using HMMcopy readcounter option (https://github.com/shahcombio/
Readcounts were generated for 1 Mb window and reads with mapping quality of greater than or equal to 20 were used. CNAs in both tumour and plasma samples were assessed using IchorCNA with matched germline sample as normal control. For plasma samples, tumour content was expected to be low, therefore estimated tumour fractions of 5, 1, 0.5 and 0.1% were used and ploidy was set to diploid. However, for tumour samples estimated tumour fractions of 50, 60, 70, 80, 90% were used and ploidy was set to 2 and 3.

Fragment size distribution
Samtools (v1.10) was used to extract reads less than 2000 bp insert size. A customised python script (provided in https://github.com/Devika1/Plasma_HiSeqXTen) was used to compute the number of reads per fragment size. We calculate the number of reads in each category (all reads, reads which have a somatic mutation, reads with a somatic mutation which is shared with tumour, reads with a somatic mutation which is unique to plasma) as a function of the length of the read, x. We calculate the ratio of shared to unique mutations for all reads with length less than or equal to x bp, as well as the ratio of unique to shared for all reads with length greater than x bp.

Results
Generation of high coverage cell-free DNA sequencing data
Matched germline, tumour and plasma samples were sequenced on Illumina HiSeqXTen and Table 1 summarizes the sequencing output achieved per sample. Sequencing coverage (Table 1) varied between samples, however expected sequencing coverage of 30X and 60X were achieved for germline and tumour DNA samples, respectively. Sequencing yield for plasma DNA samples was less than expected, nevertheless an average of 100X sequencing coverage was achieved for plasma DNA samples, representing one of the few high-coverage WGS datasets for cfDNA.

Somatic variant analysis
VarScan2 [33] was used to detect somatic single nucleotide variation (SNV) in plasma and tumour samples. DNA samples from blood buffy coat were used as germline controls to exclude germline variants in plasma and tumour samples. Somatic variants were filtered as described in Methods to identify high confidence somatic variants. Table 2 summarizes the number of somatic SNVs detected in plasma and matched tumour samples and the number of shared SNVs observed between matched tumour and plasma samples. All coding mutations in both plasma and tumour samples are provided in Additional File 1.

| Specimen Type | Sample | Number of reads | Sequencing Yield (Mb) | % Bases >= Q30 | % Duplicated reads | Sequencing Coverage |
|---------------|--------|-----------------|-----------------------|---------------|--------------------|---------------------|
| Germline DNA  | 1084_N0 | 885,589,680     | 132,838               | 83.88         | 15.82              | 35                  |
|               | 1249_N0 | 927,175,866     | 138,149               | 87.61         | 37.67              | 28                  |
|               | 1494_N0 | 830,442,242     | 123,736               | 85.08         | 27.42              | 29                  |
|               | 1524_N0 | 937,319,184     | 139,661               | 86.33         | 25.54              | 34                  |
|               | 065_N0  | 897,176,584     | 134,576               | 85.10         | 8.30               | 40                  |
|               | 098_N0  | 1,014,190,632   | 152,129               | 86.09         | 11.31              | 44                  |
| Tumour DNA    | 1084_T0 | 1,785,014,202   | 265,967               | 82.32         | 31.09              | 58                  |
|               | 1249_T0 | 1,919,380,364   | 285,987               | 83.29         | 26.70              | 67                  |
|               | 1494_T0 | 1,833,108,412   | 273,133               | 80.67         | 22.14              | 66                  |
|               | 1524_T0 | 1,819,092,474   | 271,044               | 83.42         | 24.43              | 65                  |
| Plasma DNA    | 1084_P0 | 3,978,736,468   | 592,832               | 88.76         | 25.10              | 97                  |
|               | 1249_P0 | 3,742,076,682   | 557,569               | 87.92         | 28.30              | 82                  |
|               | 1494_P0 | 3,703,572,042   | 551,832               | 89.22         | 29.78              | 83                  |
|               | 1524_P0 | 3,993,601,472   | 595,047               | 89.77         | 26.60              | 93                  |
|               | 065_P0  | 4,247,100,536   | 637,065               | 85.56         | 12.77              | 112                 |
|               | 098_P0  | 4,145,998,174   | 621,900               | 84.70         | 10.96              | 116                 |

a N0 germline, T0 tumour, P0 plasma
b Sequencing coverage was estimated using Isaac [36] provided by the sequencing provider; duplicated reads and overlapping bases are excluded for the coverage calculation
c Sequenced in a separate batch
We detected a similar number of somatic variants in all 6 plasma samples (average 4316 SNVs), whereas the number of somatic variants varied between different tumour samples (range 1120–6070 SNVs), which could be due to the inherent heterogeneity in breast cancer genomes, as well as the variable tumour purity of individual samples (sample 1249 had very low tumour purity of 14%, whereas other tumours were greater than 65%; Refer Supplementary Table 1). Approximately 4–35% of the somatic variants observed in tumour samples were detected in matched plasma samples, however these shared variants accounted for only 6–10% of the total somatic variants detected in plasma. The majority of somatic variants were unique to each plasma and tumour sample (Supplementary Fig. 1).

### Variant allele frequency

We analysed the variant allele frequency (i.e. sequence coverage for variant alleles) of somatic variants in tumour and plasma samples. We also assessed the distribution of the variant allele frequency of variants which were shared between matched tumour and plasma samples and unique variants which were only present in either tumour or plasma samples.

Variant allele frequency distribution of all somatic variants in tumour samples (Fig. 1a) varied between samples possibly due to the tumour purity of the samples (Supplementary Table 1). Similarly, variant allele frequency of shared and unique somatic variants in tumour samples differed between samples. Between 16 and 51% of the unique variants in tumour samples had less than 20%
variant allele frequency. This could explain why only 4 to 35% of the tumour mutations (Table 2) were detected in plasma samples.

Variant allele frequency distribution of all somatic variants in plasma samples (Fig. 1b) from cancer patients (samples 1084, 1249, 1494 and 1524) showed less variation between samples compared to tumour samples. Between 40 and 59% of all somatic variants in plasma samples had less than 20% variant allele frequency. Less than 30% of the shared variants in plasma samples had less than 20% allele frequency indicating that majority of the shared variants had higher variant allele frequency. Approximately 50% of the unique variants in plasma samples had allele frequency less than 20%.

**Annotation of somatic variants**

We performed gene analysis on somatic variants for both plasma and tumour samples and identified missense and nonsense mutations in several coding genes (Refer to Additional File 1). We also detected mutations in cancer associated genes reported in COSMIC Cancer Gene Census (CGC) [37] for both plasma and tumour samples. Table 3 summarises the number of mutations observed in Cosmic CGC genes (exact genomic mutation changes are provided in Additional File 2). Mutations in multiple breast cancer driver genes such as NOTCH1, PIK3CA, and TP53 were detected in tumour samples, however these mutations were not detected in matched plasma samples. Mutations in COSMIC CGC genes such as BCLAF1, MUC4, and RGPD3 were observed in multiple plasma samples. There were no mutations in Cosmic CGC which were shared between matched plasma and tumour samples.

**Somatic signatures**

Different mutational processes create characteristic mutational signatures on the genome. Hence, patterns of somatic mutations can indicate the mutational processes which have been active in a tumour. Large-scale analyses of cancer genome data across various cancer types have revealed recurrent mutational signatures [38, 39]. We used Mutational Patterns [35] to extract these mutational signatures in our samples.

Mutational changes due to C>T and T>C were predominant in both plasma and tumour samples (Supplementary Fig. 2 and Supplementary Fig. 3). We performed de-novo mutational signature detection using non-negative matrix factorization (NMF). We extracted mutational signatures and compared their relative contribution in plasma and tumour samples (Fig. 2). Based on the extracted signatures, it was evident that the mutational profiles were different between plasma and tumour samples. Signature A and Signature C was prominent in tumour samples whereas Signature B was prominent in all plasma samples (Supplementary Fig. 4).

We compared the extracted mutational profiles of plasma and tumour samples to the known COSMIC mutational signatures (version 2). Supplementary Table 2 shows the Cosine similarity [35] between the extracted signatures and COSMIC signatures. Signature A was similar to COSMIC signatures 3 and 8 (which are commonly seen in Breast cancer [40] and signature 5 (which is common to all cancers [41]), whereas Signature C was similar to signature 5. On the other hand, Signature B, which was enriched in all plasma samples, was similar to signatures 5 (common to all cancers) and 16 (found in liver cancer [42]).

We compared the mutational profiles of plasma and tumour samples directly with known COSMIC mutational signatures (version 2). Figure 3a shows the COSMIC mutational signatures observed in plasma and tumour samples. Supplementary Table 3 shows the Cosine similarity for the mutational profiles and COSMIC signatures. Signature 5 was observed in all plasma and tumour samples and notably had higher contribution in plasma samples compared to matched tumour samples. Signature 5 has been found in all cancer types and the aetiology is unknown [41]. Signature 16 was also present in all plasma samples. Signature 16 has been found in liver cancer and the aetiology is unknown [42]. Signatures 1, 3 and 8 were found in multiple tumour samples. Signature 3 has been found in breast, ovarian, and pancreatic cancers, and associated with failure of DNA double-strand break-repair by homologous recombination.
and signature 8 is found in breast cancer and medulloblastoma and the aetiology is unknown [40]. There were not any significant differences in COSMIC mutational signature contribution between plasma samples from benign tumour patients (065_P0 and 098_P0) and cancer patients. The relative contribution of COSMIC mutational signatures in plasma and tumour samples is shown in Supplementary Fig. 5.

We assessed the mutational signatures in plasma samples for somatic mutations which were shared with matched tumour and somatic mutations which were unique to plasma (i.e. not detected in matched tumour) (Fig. 3b). The contribution of Signature 5 was more prominent in unique mutations compared to shared mutations. Signatures which were prominent in tumour samples, such as signatures 1, 3 and 8 (Fig. 3a) were
also observed in plasma shared mutations. Comparison with unique mutations in plasma and tumour samples revealed that Signature 5 was present in all samples (Supplementary Fig. 6). However, Signature 5 was more prominent in plasma unique mutations compared to tumour unique mutations. This indicates that the unique mutations in plasma samples contain mutations which are different from tumour and possibly acquired from somatic changes in other tissues.

**Analysis of somatic CNAs**

Somatic CNAs in both plasma and tumour samples was detected using IchorCNA [18]. For both plasma and tumour samples matched germline DNA was used as control. Various somatic CNAs were detected in all 4 tumour samples and tumour fraction determined by IchorCNA was 70, 13, 41 and 33% for 1084_T0, 1249_T0, 1494_T0 and 1524_T0 samples, respectively. However, somatic CNAs were not detected in any of the plasma samples and estimated tumour fractions were less than 1% for all 6 plasma samples. Figure 4 shows the somatic CNAs detected in sample 1084 tumour and matched plasma sample. IchorCNA plots for all other samples are provided in Supplementary Fig. 7.

We also used all 6 plasma samples as a combined normal panel for plasma sample analysis; however, it did not identify any somatic CNAs in plasma samples. We used our in-house tool sCNASeq [43] to detect somatic CNAs, but it also failed to detect any somatic CNAs in plasma samples. This is likely due to the low tumour content in the plasma samples and the analysis approaches are not sensitive enough to analyse low tumour content samples despite high sequencing coverage in the samples.

**Fragment size analysis**

Plasma DNA fragments exhibit a unique fragment length profile due to the nucleosome positioning; hence the majority of the cfDNA fragments are approximately 166bp (mono-nucleosome size) and multiples thereof. We assessed the fragment length distribution of all reads with less than 2000bp insert size and observed the expected fragment size distribution pattern for cfDNA (Supplementary Fig. 8). We extracted all somatic reads which contain a somatic SNV (Refer to Methods) and assessed the fragment length distribution of somatic reads. We further grouped the somatic reads based on the somatic SNVs which were shared or not shared (i.e., unique) with matched tumour samples and explored the differences in fragment length between all reads, somatic reads, somatic shared reads and somatic unique reads for both cancer patients and benign tumour patients. We noticed differences in fragment length profile between somatic reads and all reads in all plasma samples (Fig. 5a). There was not any difference in somatic fragment length distribution between cancer patients and benign tumour patients.

Fragment length comparison between somatic shared reads and somatic unique reads in tumour patients revealed that tumour-derived fragments (i.e., somatic shared reads) were enriched in fragments 300bp -350bp
compared to somatic unique reads (Fig. 5b). We found a higher proportion of somatic shared reads were enriched in fragments within the di-nucleosome peak compared to somatic unique reads (Fig. 5a and b). This suggests that some tumour-derived fragments could be longer and less fragmented. Higher enrichment of tumour-derived shared fragments in the longer size range indicates that it could be feasible to selectively enrich fragments between 300 and 400 bp to enrich for tumour-derived fragments in plasma samples.

**Discussion**

Currently ctDNA analysis are often performed using targeted sequencing of small panels of genes or known hotspot mutations in key cancer genes. Low-coverage WGS analysis of cfDNA is often performed for detection of somatic CNAs. To-date, only a handful of studies have performed high-coverage WGS (20-50x coverage) of cfDNA for tumour analysis [8, 25]. Use of high-coverage WGS for cfDNA analysis is mainly constrained due to the high cost of sequencing. However, it has the potential to discover all somatic changes in cfDNA samples. In this study, we performed deep sequencing analysis of cfDNA samples to explore its utility for detection of tumour-derived somatic changes in samples with low tumour content and to improve our understanding on the biology of cfDNA. The sequencing data generated in this study is one of the highest coverage cfDNA sequencing data with matched tumour sequencing data. This could be a valuable resource for researchers working in non-invasive diagnostic approaches to develop novel analytical methods and to understand the biological characteristics of cfDNA.

Despite the high sequencing coverage, we only detected less than 10% of somatic SNVs in plasma which were shared with matched tumour. One of the main reasons for this is the low-tumour content in the plasma samples. The CNA analysis estimated that the tumour content in the samples to be less than 1%. Theoretically with 100X coverage, a variant with 1% allele frequency would only have 1 variant supporting read, which is not sufficient to reliably call the variant allele. Variation in sequence coverage across the genome could detect these low frequency variants. It was evident from the allele frequency distribution analysis that greater than 70% of the shared variants in the plasma samples had greater than 20% variant allele frequency, indicating that only high frequency tumour variants were detected in the matched plasma.

![Fig. 4 Somatic CNAs detected in patient 1084 (a) tumour and (b) plasma samples. Copy number across chromosome 1 to 22 are plotted. The colour of the data points denotes copy number; dark green - 1 copy, blue - 2 copy, brown – 3 copy and red – 4 copy. Light green horizontal line represents a subclonal prediction.](image)
We performed a stringent variant filtering for somatic variant analysis to reduce false positives. Only 32–45% of the tumour mutations were detected in plasma samples. Variant allele frequency distribution indicated that the variants which were not detected in plasma were mostly low frequency variants. However, some of the key tumour driver mutations such as TP53 and PICK3CA had high variant allele frequency in tumour, yet these were not detected in plasma. This could be due to the detection limit of the somatic variant caller we have used and may be resolved by other somatic mutation detection tools such as Mutect [44] and LoFreq [45], however their detection sensitivity for low frequency variants needs to be explored. Though, VarScan2 combined with strict variant filtering as performed in our study is recommended for detecting low frequency mutations [46].

Greater than 90% of the somatic mutations detected in plasma samples were unique to plasma samples. Most studies to date on plasma somatic variant analysis have only used targeted sequencing and they have also reported mutations in plasma samples which were not detected in matched tumour samples (approximately 50–90% of variants were not shared with matched tumours) [18, 47]. One of the possible reasons for this divergence could be the bias in tumour sampling and associated tumour heterogeneity, where only a fraction of the tumour is sampled and analysed. Some of the somatic mutations identified in the plasma could have been
present in the tumour, but it might not been present in
the precise piece of tumour sequenced, due to sampling
variations. Also, the presence of metastatic tumours
could also contribute to somatic variations in the plasma.

The mutational burden of the plasma samples (average
1.44 somatic mutations/Mb of genome) was higher than
the tumour samples (average of 0.94 somatic mutations/
Mb of genome). High-coverage targeted sequencing of
gene panels on plasma of controls and cancer patients
have revealed mutations due to clonal hematopoiesis [48,
49] and often most of these mutations were detected in
matched blood samples in low-frequency. Clonal hematopoi-
oesis describes the expansion of a clonal population
of hematopoietic stem cells regardless of disease state
[50, 51]. These contribute to low-frequency somatic
clones in blood, which are released into plasma and then
detected in plasma cfDNA. Although, in this study we
used matched blood samples to exclude germline vari-
ants, it is likely some of the low-frequency variants in the
blood samples were not detected due to relatively low-
coverage (30x) of germline DNA samples compared to
plasma DNA samples. Hence, it is possible that some of
the somatic mutations detected in the plasma samples in
our study could have been due to clonal hematopoiesis.

The other possible explanation for higher muta-
tional burden in plasma samples, could be due to clonal
somatic changes in germline tissues. Multiple somatic
variants were identified in normal tissues suggesting a
macroscopic clonal expansions in normal tissues lead-
ing to somatic mosaicism [52, 53]. Given that plasma
cfDNA contains DNA from various organs and tis-
sues [4, 5], any somatic changes in these cells could
be detected in plasma. Hence it is possible that some of
these somatic variants in plasma are derived from
other tissues. However, methylation or transcriptomic
or nucleosome positioning analysis needs to be per-
formed to ascertain what fraction of somatic variants
are derived from other tissues.

Mutational signature analysis on plasma samples
revealed higher contribution of signature 5, which has
been found in all cancer types and most cancer samples
[38, 39]. Furthermore, unique somatic mutations in
plasma samples had higher contribution of signature 5
compared to shared somatic mutations indicating that
these mutations are distinct to tumour-derived mu-
tations. It has been reported that Signature 5 is driven by
the loss of FHIT gene [41]. Depletion of FHIT causes
replication stress-induced DNA double-strand breaks
and defects in replication fork progression and pre-
vents activation of DNA damage response [54]. It is
likely that the majority of somatic mutations in plasma
are likely due to the result of replication errors and lack
of DNA damage responses.

Tumour-derived somatic CNAs are detected in
plasma samples of cancer patients using low-coverage
WGS [21, 22]. However, samples with high tumour
content are often used in these analyses. Plasma sam-
ple in our study had low tumour content, hence
detection of somatic CNAs was not feasible. Most
somatic CNA detection tools use large number of nor-
mal cfDNA samples as a reference panel. Although
IchorCNA could use single matched germline sample
as the normal control, performance of CNA detection
is improved with large normal panels [18]. Due to the
lack of large normal cfDNA high coverage WGS data, it
was not feasible to detect somatic CNAs in low tumour
content samples, despite high sequencing coverage.

Cell-free DNA fragments commonly show a promi-
nent peak at 166 bp, due to nucleosome positioning and
suggesting apoptosis based DNA fragmentation [5, 55].
Size distribution of tumour-derived DNA have revealed
enrichment in fragment sizes between 90 and 150 bp
for multiple tumour types [56] and longer ctDNA frag-
ments (> 1000 bp) are also enriched in some cancer
types [57]. However, we did not detect any enrichment
in tumour-derived fragments in < 150 bp, this is likely
due to the low tumour content in our plasma DNA
samples. Mouliere et al. (2018) have demonstrated that
low ctDNA samples have less fragments below 150 bp
compared to samples with high ctDNA content [56].
We detected an enrichment in somatic shared frag-
ments in 300 bp - 350 bp, indicating higher fraction of
tumour-derived fragments in cfDNA di-nucleosome
peak. Higher enrichment in the longer fragment range
of 300 bp - 350 bp indicates that it could be feasible
to selectively enrich these longer size fragments to
improve the detection sensitivity of tumour-derived
fragments in plasma samples with low tumour content.

It was evident from our analysis, that despite the high
sequencing coverage of 100X in plasma samples, it was
not sufficient to detect all somatic changes in low-tumour
content samples. We believe the sequencing dataset gen-
erated in this study will be valuable for other researchers
to develop novel analytical tools to improve the detection
sensitivity for somatic changes and to further explore the
characteristics of cfDNA.

Conclusion
In summary, high-coverage WGS analysis of cfDNA
samples revealed a large fraction of unique somatic vari-
ants in plasma, which are likely derived from somatic
clonal changes in germline tissues. Characteristics of
these somatic mutations are different to the tumour-
derived somatic mutations in plasma samples. High-
coverage WGS analysis did not detect all tumour-derived
somatic changes in samples with low-tumour content.
Nevertheless, it did improve our understanding on the biology of cfDNA and this study provides a valuable high-coverage WGS dataset of cfDNA to facilitate further research.

Abbreviations
cfDNA: Cell-free DNA; ctDNA: Circulating tumour DNA; WGS: Whole genome sequencing; SNVs: Single nucleotide variants; CNAs: Somatic copy number aberrations.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-09160-1.

Acknowledgements
We thank patients and staff who contributed to the Brisbane Breast Bank. We acknowledge the support of Metro North Hospital and Health Services in the collection of the Clinical Subject Data and Clinical Subject Materials.

Authors’ contributions
DG, PTS and LC conceived the study. DG performed library preparation, somatic variant analysis, mutational signature analysis, copy number analysis and wrote the paper with input from the other authors. AR performed sequencing data QC, mapping of sequencing data and copy number analysis. WC performed somatic variant analysis and copy number analysis. MBH performed fragment size analysis. MDC performed extraction of somatic DNA sequencing data QC, mapping of sequencing data and copy number analysis. All authors read and approved the final manuscript.

Availability of data and materials
The datasets supporting the conclusions of this article are available in the European Genome Archive (EGA) repository, under data accession number EGAD00001006869 (https://ega-archive.org/datasets/EGAD00001006869).

Declarations
Ethics approval and consent to participate
These patients were recruited as part of a study by Brisbane Breast Bank, which was approved by the Human Research Ethics Committee at the University of Queensland (project ID: 2005000785) and the Royal Brisbane and Women’s Hospital (ref. 2005/022). Written informed consent were obtained from participants.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 30 June 2021 Accepted: 27 December 2021
Published online: 20 January 2022

References
1. Chan AKC, Chiu RWK, Lo YMD. Clinical sciences reviews Committee of the Association of clinical biochemists: Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem. 2003;40:122–30.
2. Lui YYN, Chik K-W, Chiu RWK, Ho C-Y, Lam CWK, Lo YMD. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem. 2002;48:421–7.
3. Sun K, Jiang P, Chen KCA, Wong J, Cheng YW, Liang H, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112:E5503–12.
4. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9:5068.
5. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164:57–68.
6. Stoun M, Anker P, Pauwels P, Loyer N, Corach A, et al. Non-invasive characterization of the DNA found in the plasma of cancer patients. Oncology. 1989;46:318–22.
7. Chan KCA, Lo YMD. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer. 2007;96:681–5.
8. Chan KA, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and Tumoral heterogeneity by massively parallel sequencing. Clin Chem Oxford Academic. 2013;59:216–24.
9. Bettegowda C, Sausen M, Leary RJ, indel K, Wang Y, Agravat N, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med. 2014;6:224ra24.
10. Esposito A, Bardelli A, Criscitiello C, Cobolombo N, Gelao L, Funagalli L, et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat Rev. 2014;40:648–55.
11. Murtaza M, Dawson S-J, Tsui DWY, Gale D, Fordhew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497:108–12.
12. Fordhew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Non-invasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra68.
13. Garcia-Murillas I, Schiavon G, Weigelt B, Ngc C, Rehbien S, Cutts RI, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:302ra133.
14. van Ginkel JH, Huibers MMH, van Es RJU, de Bree R, Willems SM. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. BMC Cancer. 2017;17:428.
15. Zhu G, Ye X, Dong Z, Lu YC, Sun Y, Liu Y, et al. Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non–small cell lung Cancer. J Mol Diagn. 2015;17:265–72.
16. Geversleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res. 2013;19:3276–84.
17. Kim ST, Lee W-S, Lamman RB, Mortimer S, Zill OA, Kim K-M, et al. Prospective blinded study of somatic mutation detection in cell-free DNA
utilizing a targeted 54-gene next generation sequencing panel in meta-
static solid tumor patients. Oncotarget. 2015;6:40360–9.
18. Adalsteinsison VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons
HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high
concordance with metastatic tumors. Nat Commun. 2017;8:1324 Nature
Publishing Group.
19. Newman AM, Britman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An
ultrasensitive method for quantitating circulating tumor DNA with broad
patient coverage. Nat Med. 2014;20:548–54.
20. Heitze E, Utz P, Belic J, Gutsch S, Quenenberger F, Fischereder K, et al. Tumor-
associated copy number changes in the circulation of patients with prostate
cancer identified through whole-genome sequencing. Genome Med.
2013;5:30.
21. Hovelson DH, Liu C-J, Wang Y, Kang Q, Henderson J, Gursky A, et al. Rapid,
ultra low coverage copy number profiling of cell-free DNA as a precision
oncology screening strategy. Oncotarget. 2017;8:98948–66.
22. Chen X, Chang C-W, Spoerke JM, Yoh KE, Kapoor V, Baudo C, et al. Low-
pass whole-genome sequencing of circulating cell-free DNA demonstra-
stes dynamic changes in genomic copy number in a squamous lung
Cancer clinical cohort. Clin Cancer Res. 2019;25:2254–63.
23. Roy NV, Linden MVD, Menten B, Dheedene A, Vandeputte C, Dorpe J, et al. Shallow
whole genome sequencing on circulating cell-free DNA allows reliable noninvasive copy-number profiling in neuroblastoma
patients. Clin Cancer Res. 2017;23:6305–12.
24. Zhou Q, Moser T, Perakis S, Heitzer E. Untargeted profiling of cell-free
circulating DNA. Transl Cancer Res. 2017;7:5140–52.
25. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of Chromosomal Alterations in the Circulation of Cancer Patients
with Whole-Genome Sequencing. Sci Transl Med. 2012;4:162ra154.
26. Reed AEM, Saunus JM, Ferguson K, Niland C, Simpson PT, Lakhani SR. The
Brisbane Breast Bank. Open J Biosci. 2018;5:5.
27. Babraham Bioinformatics - FastQC. A Quality Control tool for High
Throughput Sequence Data [Internet]. [cited 2020 Jun 21]. Available from:
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
28. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flextrimmer for Illu-
mination data. Bioinformatics. 2014;30:2114–20.
29. FASTX-Toolkit [Internet]. [cited 2020 Jun 21]. Available from: http://hannon
lab.cshl.edu/fastx_toolkit/index.html
30. Li H. Aligning sequence reads, clone sequences and assembly contigs
with BWA-MEM. ArXiv13033997 Q-Bio [Internet]. 2013; Available from:
http://arxiv.org/abs/1303.3997
31. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence
alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.
32. Picard Tools - By Broad Institute [Internet]. [cited 2020 Jun 21]. Available from:
http://broadinstitute.github.io/picard/
33. Koboldt DC, Zhang Q, Larson DE, Chen D, McLellan MD, Lin L, et al. VarScan
2: somatic mutation and copy number alteration discovery in cancer
by exome sequencing. Genome Res. 2012;22:2568–76.
34. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic
variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.
35. Blokzijl F, Jannsen R, van Boxtel R, Cuppen E. MutationalPatterns: comprehen-
sive genome-wide analysis of mutational processes. Genome Med.
2018;10:33.
36. Racz C, Petrovski R, Saunders CT, Chorny I, Kruglyak S, Margulies EH, et al. Isaac: ultra-fast whole-genome secondary analysis on Illumina sequenc-
ing platforms. Bioinformatics. 2013;29:2041–3.
37. Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC
Cancer gene census: describing genetic dysfunction across all human
cancers. Nat Rev Cancer. 2018;18:696–705 Nature Publishing Group.
38. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Blankin
AV, et al. Signatures of mutational processes in human cancer. Nature.
2013;500:415–21 Nature Publishing Group.
39. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature.
2020;578:94–101 Nature Publishing Group.
40. Angus L, Srid M, Witting SM, van Riet J, Van Hoeck A, Nguyen L, et al. The genomic landscape of metastatic breast cancer highlights changes in
mutation and signature frequencies. Nat Genet. 2019;51:1450–8 Nature Publishing Group.
41. Volini S, Druck T, Passie CA, Schrock MS, Huebner K. The ubiquitous
‘cancer mutational signature’ 5 occurs specifically in cancers with deleted
FHIT alleles. Oncotarget. 2017;8:102199–211.
42. Letouzé E, Shinde J, Renault V, Coughy G, Blan C-JF, Tubacher E, et al. Mutational
signatures reveal the dynamic interplay of risk factors and cellular
processes during liver tumorigenesis. Nat Commun. 2017;8:1315
Nature Publishing Group.
43. Robertson AJ, Xu Q, Song S, Ganesamoorthy D, Benson D, Chen W, et al. Profiling copy number alterations in cell-free tumour DNA using a single-
reference: bioRIV. 2018;1:290171 Cold Spring Harbor Laboratory.
44. Benjamin D, Sato T, Cibuikss K, Getz G, Stewart C, Lichtenstein L. Calling
Somatic SNVs and Indels with Mutect2. bioRIV. 2019;1:861054 Cold
Spring Harbor Laboratory.
45. Wilm A, Av PPK, Bertrand D, Yeo GHT, Ong SH, Wong CH, et al. LoFreq: a
sequence-accuracy aware, ultra-sensitive variant caller for uncovering
cell-population heterogeneity from high-throughput sequencing datasets.
Nucleic Acids Res. 2012;40:11189–201.
46. Chen S, Liu M, Zhou Y. Bioinformatics analysis for cell-free tumor DNA
sequencing data. Methods Mol Biol Clifton NJ. 1754:2018:67–95.
47. Butler TM, Johnson-Camacho K, Peto M, Wang NJ, Macy TA, Korkola
JE, et al. Exome Sequencing of Cell-Free DNA from Metastatic Cancer
Patients Identifies Clinically Actionable Mutations Distinct from Primary
Disease. Plos One. 2015;10:e0136407 Public Library of Science.
48. Liu J, Chen X, Wang L, Zhe S, Wang CL, Ye MZ, et al. Biological back-
ground of the genomic variations of cf-DNA in healthy individuals. Ann
Oncol Evolving. 2019;30:646–70.
49. Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity
sequencing reveals the sources of plasma circulating cell-free DNA vari-
ant. Nat Med. 2019;25:1928–37.
50. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease.
Science. 2019;366:aear4673.
51. Bowman RL, Busque L, Levine RL. Clonal hematopoiesis and evolution
to hematopoietic malignancies. Cell Stem Cell. 2018;22:157–70.
52. García-Nieto PE, Morrison AJ, Fraser HB. The somatic mutation landscape
of the human body. Genome Biol. 2019;20:298.
53. Yizhak K, Aguet F, Kim J, Hess JM, Kübler K, Grimsby J, et al. RNA sequence
analysis reveals macroscopic somatic clonal expansion across normal
tissues. Science. 2019;364:aearw0726.
54. Saldivar JC, Park D. Mechanisms shaping the mutational landscape of
the FRA3B/FHIT-deficient cancer genome. Genes Chromosomes Cancer.
2019;58:317–23.
55. Lo YMDC, Chan KCA, Sun H, Chen EJ, Jiang P, Lun FMY, et al. Maternal
dna DNA sequencing reveals the genome-wide genetic and muta-
tional profile of the fetus. Sci Transl Med. 2010;2:ra91.
56. Mouliere F, Chandrananda D, Pickorz AM, Moore CK, Morris J, Ahlborn
LB, et al. Enhanced detection of circulating tumor DNA by fragment size
analysis. Sci Transl Med. 2018;10:eaat4921.
57. Ponti G, Maccarelli M, Manfredini M, Miculà S, Troncelli F, Millandt R, et al. Quick
assessment of cell-free DNA in seminal fluid and fragment size for early non-
invasive prostate cancer diagnosis. Clin Chim Acta. 2019;497:76–80.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.